Pentoxifylline

Blood Viscosity Reducer — CARDIOVASCULAR SYSTEM

Key facts

Pentoxifylline is an ofp drug in the Blood Viscosity Reducer class catalogued in DrugCentral. It was first approved by the FDA in 1984. DrugCentral lists 4 molecular targets, including ADORA2B, ACHE and PDE4B. Recorded indications include Peripheral vascular disease.

• Approval status: ofp (first approved 1984 by the FDA).
• Drug class: Blood Viscosity Reducer.
• Molecular targets: ADORA2B, ACHE, PDE4B and PDE5A (4 listed in DrugCentral).
• Indications: Peripheral vascular disease.
• ATC code: C04AD03 (Purine derivatives).
• Molecular formula: C13H18N4O3; molecular weight 278.31 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Peripheral vascular disease

Off-label uses (2)

• Alcoholic hepatitis
• Osteoradionecrosis

Contraindications (5)

• Bleeding
• Blood coagulation disorder
• Hemorrhagic cerebral infarction
• Kidney disease
• Retinal hemorrhage

Mechanism & targets

• Established pharmacologic class: Blood Viscosity Reducer

Molecular targets (4)

Target	Gene	Action	Activity
Adenosine receptor A2b	ADORA2B	antagonist	Ki 5.29
Acetylcholinesterase	ACHE	unknown	IC50 5.18
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	PDE4B	inhibitor	—
cGMP-specific 3',5'-cyclic phosphodiesterase	PDE5A	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1984-08-30	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C04AD03	CARDIOVASCULAR SYSTEM › PERIPHERAL VASODILATORS › PERIPHERAL VASODILATORS › Purine derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Amaurosis fugax	748.6
Haemorrhagic stroke	674.6
Ocular discomfort	639.1
Urinary tract disorder	610.8
Head discomfort	561.3
Generalised oedema	469.9
Blindness	461.7
Altered state of consciousness	443.1
Haematemesis	440.8
Eye pain	402.6
Presyncope	401.1
Diplopia	385.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Pentoxifylline is on its molecule page.

• Molecular formula: C₁₃H₁₈N₄O₃
• Molecular weight: 278.31 g/mol
• CAS number: 6493-05-6
• InChIKey: BYPFEZZEUUWMEJ-UHFFFAOYSA-N
• PubChem CID: 4740

CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pentoxifylline used for?

DrugCentral lists the following indications for Pentoxifylline: Peripheral vascular disease.

How does Pentoxifylline work?

Its molecular targets in DrugCentral include ADORA2B (antagonist), ACHE, PDE4B (inhibitor) and PDE5A (inhibitor).

When was Pentoxifylline first approved?

Pentoxifylline was first approved by the FDA in 1984.

What drug class does Pentoxifylline belong to?

Pentoxifylline is in the Blood Viscosity Reducer class.

What is the chemical formula of Pentoxifylline?

Pentoxifylline has the molecular formula C13H18N4O3 and a molecular weight of 278.31 g/mol.

Sources

• DrugCentral drug card 2099 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL628 — compound record and bioactivity
• PubChem CID 4740 — chemical identifiers
• DrugBank DB00806 — drug record
• FDA UNII SD6QCT3TSU — substance identity
• DailyMed: FDA labels for Pentoxifylline — current prescribing information (label search)
• UniProt P29275 (ADORA2B) — target protein
• UniProt P22303 (ACHE) — target protein
• UniProt Q07343 (PDE4B) — target protein
• UniProt O76074 (PDE5A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.